The pharmaceutical industry has called for abolishing “off-year” drug price revisions in the run-up to the formulation of the 2024 Basic Policy on Economic and Fiscal Management and Reform (honebuto) later in June. It appears that its lobbying efforts have…
HOME > REGULATORY
REGULATORY
- US Proposes Elimination of Tariff on Drugs: TPP Talks
September 14, 2011
- MHLW to Continue to Promote Non-proprietary Name-based Brand Names for GE Drugs
September 14, 2011
- ”GMP Team” to Begin Mock GMP Inspections in Kinki Region from Next February
September 14, 2011
- MHLW Permits Ongoing Internet Sales of Reclassified Class 2 Drugs as Provisional Measure
September 13, 2011
- MHLW Minister Komiyama to Push Drug Industry Development Through Government-Private Sector Cooperation
September 13, 2011
- PAFSC: “No Direct Correlation” Between HPV Vaccine and Reported Death
September 13, 2011
- MHLW Director-General Kikura Indicates “Firm Resolve” for Structural Improvement to Eliminate Drug Disasters
September 12, 2011
- Japan-China Pharma Regulators to Start 4 Projects to Boost Cooperation
September 12, 2011
- Regulatory Strategy Consultation Service “Not Off to a Good Start”: Mr Masuyama of PMDA
September 12, 2011
- Dispensing Fees per Prescription Down in FY2010 for 1st Time in 4 Years: Korosho
September 12, 2011
- MHLW Designates 6 Products Including ruxolitinib as Orphan Drugs
September 9, 2011
- Medical Costs Reduced ¥7 Bil. by Promoting Use of GEs: JHIA
September 9, 2011
- MHLW’s Council to Draw Up 10-Year Strategy for Hepatitis
September 9, 2011
- Council Recommends Subsidization of Peginterferon Therapy for Chronic Active Hepatitis B
September 9, 2011
- CSIMC Recommends NHI Price Listing for 15 APIs/20 Products
September 8, 2011
- Generic Dispensing Not Promoted in Pharmacies: CSIMC’s Subcommittee
September 8, 2011
- CSIMC Introduces New Rule for Pricing of High-Priced Drugs; 10 Drugs to Be Reimbursed on Piecework under DPC
September 8, 2011
- Some CSIMC Members Question NHI Pricing of Nexium Priced at Lower Level Than Omepral
September 8, 2011
- CSIMC Recommends NHI Price Listing for 15 APIs/20 Products
September 7, 2011
- MHLW Senior Vice Minister Tsuji, Parliamentary Secretary Fujita in Charge of Medical, Nursing Fee Revision
September 7, 2011
ページ
The pharmaceutical industry is ever-changing. Recruiters must evolve accordingly and prepare well in advance for future talent needs.This means predicting the changes and trends that will impact the market, industry, and your organization, and how this will affect talent requirements.…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…